Participants including clinicians, researchers, FDA and global health authorities, industry partners, patients, and the Amyloidosis Research Consortium (ARC) will detail the Amyloidosis Forum stakeholder working groups’ projects to accelerate drug development in AL and ATTR Amyloidosis.
